Is Venetoclax Retreatment Effective in Relapsed CLL?
A review of clinical evidence indicates that venetoclax re-exposure is associated with high response rates in patients with relapsed chronic lymphocytic leukemia (CLL). The overall response rates ranged from 72% to 100%, while median progression-free survival varied between 23 to 58 months. However, the evidence remains preliminary, with heterogeneous patient populations and varying treatment regimens complicating direct comparisons.
- ▪Venetoclax re-exposure was associated with high overall response rates and promising progression-free survival in selected patients with relapsed CLL.
- ▪The overall response rates ranged from 72% to 100%, with undetectable minimal residual disease rates in peripheral blood ranging from 32% to 92%.
- ▪Median progression-free survival after retreatment varied across cohorts from approximately 23 to 58 months.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/venetoclax-retreatment-effective-relapsed-cll-2026a1000he0?src=rss |
| Publication time | Wed, 27 May 2026 03:56:38 EDT |
| Retrieval time | 2026-05-27T08:07:57.149Z |
| Last seen | 2026-05-27T08:07:57.149Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | H14Iak5Hcaed |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:Venetoclax re-exposure — usually in combination with an anti-CD20 antibody or a Bruton tyrosine kinase (BTK) inhibitor — was associated with high overall response rates and promising progression-free survival (PFS) in selected patients with relapsed chronic lymphocytic leukemia (CLL), according to a review of clinical evidence. Across several studies, the overall response rates ranged from 72% to 100%, with rates of undetectable minimal residual disease in peripheral blood ranging from 32% to 92%. Median PFS ranged from approximately 23 to 58 months.METHODOLOGY:Fixed-duration venetoclax combinations are widely used in both frontline and relapsed or refractory CLL.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
